Further to yesterdays WSJ article (above) about Roche buying a phase 2 drug for $US 7bill, here is a very fascinating follow up article - highlighting a number of familiar & very relevant points to RAC/bisantrene, namely
1) BP 'will often overlook one of their own hot prospects'. Sound familiar ?
2) BP is more than happy for biotechs to 'shoulder the heavy costs' of developing a drug
3) The mega blockbuster potential for drugs that work in multipe indications
4) How quickly a deal can occur, at any time
5) Very high prices can be & are paid for phase 2, non FDA approved drugs
Another timely reminder of what we potentially have here with bisantrene !
https://archive.is/1Nt33
Industry news, page-1489
-
- There are more pages in this discussion • 473 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.52 |
Change
-0.030(1.94%) |
Mkt cap ! $258.9M | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.57 | $1.50 | $75.34K | 49.79K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.52 | 49256 | 1 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |